CPhI Worldwide experts advocate single reference product for generics and '3D printed personalized formulations'

CPhI Worldwide, organized by UBM EMEA, today announces the findings of part iii of the 2016 CPhI Annual Report, which focuses on growth opportunities over the next five years – specifically generics consumption and approval process, the use of big data in pharma and the potential of 3D printed formulations.

The overall findings reveal pharma may now be on cusp of new age of high-tech applications, as new technologies begin to imbed in pharma and the industry reimagines the art of the possible – with potential new drugs targets identified using far larger data sets and computational analysis. In terms of manufacturing, drugs could be individually 3D printed to a patient’s requirements (dose, release profile and combinations). In generics, overall growth is predicted to continue to expand rapidly, but with the caveat that faster approvals are need to improve time to market and patient benefit.

Fewer generic opportunities expected